Search
BIO 2026: Vir is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker here
President & CEO Marianne De Backer describes the unmet need in Hepatitis Delta and why she believes the dual antibody + siRNA is the right approach in this case. Plus, how investors thing about infectious disease vs oncology. Coverage brought to you by
Jun 24
ASCO 2026: Vir Biotechnology CEO Marianne De Backer discusses the company's masked T-cell engager platform, which recently earned the company a partnership with Astellas on PSMA
She describes Vir's PRO-XTEN masking technology and why she believes it has advantages vs others in development. Plus, a summary of the company's PSMA data, and how she believes the masking technology has played such a critical role.
May 30
Biotech CEO Sisterhood: Vir's CEO Marianne De Backer describes her background and leadership style, and joining Vir as it experienced a road bump, but turning it into an opportunity via a key IO deal
Interviewed by Sisterhood editorial board member Grace Colón, Marianne De Backer advocates for the importance of getting experience in a...
Mar 3, 2025
Marianne De Backer talks about joining Vir Biotechnology and shares her vision for the future
Vir's new CEO gives an overview of the company's programs and discusses future plans to expand into autoimmune disease and oncology.
Dec 5, 2023
.png){kind=logo}